Nilotinib Stada (Nilotinib)

Nilotinib binds selectively to the ATP‑binding pocket of the BCR‑ABL tyrosine‑kinase fusion protein. This blocks the enzyme’s activity, halting downstream signaling pathways that promote uncontrolled cell division. By inhibiting BCR‑ABL, nilotinib induces apoptosis in leukemic cells while sparing most normal tissues.

The specific dose of Nilotinib Stada is determined by the prescribing clinician based on the patient’s disease status, body weight, renal and hepatic function, and other individual factors. Healthcare professionals follow approved prescribing information and adjust the regimen as needed for safety and efficacy.

The safety of nilotinib in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug may pose risks to the fetus or infant. Use only if the potential benefit justifies the potential risk, and discuss alternatives with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor that offers higher potency against many resistant BCR‑ABL mutations compared with first‑generation agents like imatinib. It has a distinct safety profile, including a higher risk of QT prolongation, and may be chosen when patients require a more potent option or have specific mutation patterns.

Nilotinib Stada tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight to maintain stability throughout its shelf life.

Nilotinib Stada is taken orally, usually as whole tablets with a low‑fat meal. Patients should swallow the tablets whole with water and follow the dosing schedule prescribed by their clinician, ensuring consistent timing and food conditions to optimize absorption.

The most serious risks include QT interval prolongation, which can lead to potentially fatal arrhythmias, severe liver toxicity, and pancreatitis. Patients should undergo regular cardiac monitoring, liver function tests, and pancreatic enzyme assessments, and report any symptoms such as palpitations, jaundice or severe abdominal pain promptly.

Nilotinib Stada is contraindicated in patients with a known hypersensitivity to nilotinib or any of its excipients, and in individuals taking strong CYP3A4 inhibitors or drugs that significantly prolong the QT interval. It should also be avoided in patients with uncontrolled cardiac arrhythmias or severe hepatic impairment.